The COX18 antibody targets the COX18 protein, a key component involved in the biogenesis of cytochrome c oxidase (Complex IV), the terminal enzyme in the mitochondrial electron transport chain (ETC). Cytochrome c oxidase catalyzes the transfer of electrons from cytochrome c to molecular oxygen, driving ATP synthesis. COX18. also known as MITRAC18. is an integral membrane protein localized to the mitochondrial inner membrane. It functions as an assembly factor, facilitating the incorporation of subunit COX2 into the enzyme complex, particularly during copper ion insertion—a critical step for catalytic activity.
COX18 antibodies are essential tools for studying mitochondrial respiratory chain disorders, neurodegenerative diseases, and metabolic syndromes linked to ETC dysfunction. Researchers use these antibodies in techniques like Western blotting, immunofluorescence, and immunoprecipitation to assess COX18 expression levels, subcellular localization, and interactions with other assembly factors. Altered COX18 expression or mutations have been implicated in mitochondrial encephalopathies and Leigh syndrome, highlighting its role in maintaining energy metabolism. Additionally, studies on COX18 contribute to understanding cellular responses to oxidative stress and hypoxia, as ETC efficiency directly impacts reactive oxygen species (ROS) production. Commercially available COX18 antibodies are typically raised in rabbits or mice, validated for specificity across human, mouse, and rat models, supporting translational research in mitochondrial biology and disease mechanisms.